CompletedNCT03247530
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) Low Dose in Children With ADHD
Researchers compared 100mg SPN-812, 200mg SPN-812 and placebo to find out how the approaches affected ADHD symptoms in children with ADHD.
Medication studyAges 6–11United States
Understand this study
What did researchers investigate?
Researchers compared 100mg SPN-812, 200mg SPN-812 and placebo to find out how the approaches affected ADHD symptoms in children with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 11 years. Other eligibility criteria applied.
- Listed locations
- Dothan, United States · Hialeah, United States and 5 more locationsSee all locations and recruitment
- Activities
- Placebo comparator · Medication described in the protocol
- Compensation
- Payment and expense reimbursement have not been verified.
Study information
Study start dateStarted: October 20, 2017
- Recruitment status
- Completed
- Enrollment listed in the registry
- 477
- Sponsor
- Supernus Pharmaceuticals, Inc.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- United States
- Age range
- From 6 Years to 11 Years
- Official registry ID
- NCT03247530
- Official title
Show the full official title
Evaluation of SPN-812 (Viloxazine Extended-release Capsule) 100 and 200 mg Efficacy and Safety in Children With ADHD - A Double-Blind, Placebo-Controlled, Pivotal Trial
Recruitment & locations
CompletedDothan · Hialeah · Meridian
4 more locations
- Rochester
- Houston
- The Woodlands
- Orem
Questions about this study
What did researchers investigate?
Researchers compared 100mg SPN-812, 200mg SPN-812 and placebo to find out how the approaches affected ADHD symptoms in children with ADHD.
Who is behind this study?
The study sponsor is Supernus Pharmaceuticals, Inc., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Placebo, 100mg SPN-812 and 200mg SPN-812.
Who was this study for?
This study was for people with ADHD. Listed age limits: 6 years to 11 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meRelated studies
A 6 Week Study of MG01CI 1400 mg Compared With Placebo in Adults With ADHD ( Attention Deficit/Hyperactivity )
NCT02059642A Classroom Study to Assess the Time of Onset of Vyvanse (Lisdexamfetamine Dimesylate) in Pediatric Subjects Aged 6-12 With Attention Deficit/Hyperactivity Disorder (ADHD)
NCT00500149